BlackRock’s ProQR Therapeutics PRQR Stock Holding History

BlackRock’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.34K	Hold	3,945	–	–	﹤0.01%	5466
2026 Q1	$6.39K	Hold	3,945	–	–	﹤0.01%	5442
2025 Q4	$7.97K	Hold	3,945	–	–	﹤0.01%	5305
2025 Q3	$8.4K	Hold	3,945	–	–	﹤0.01%	5227
2025 Q2	$8.05K	Sell	3,945 -107	-3%	-$174	﹤0.01%	5239
2025 Q1	$5.39K	Sell	4,052 -97,253	-96%	-$207K	﹤0.01%	5236
2024 Q4	$268K	Buy	101,305 +97,360	+2,468%	+$309K	﹤0.01%	4562
2024 Q3	$7.18K	Hold	3,945	–	–	﹤0.01%	5012
2024 Q2	$6.55K	Hold	3,945	–	–	﹤0.01%	5104
2024 Q1	$9.03K	Hold	3,945	–	–	﹤0.01%	5098
2023 Q4	$7.81K	Hold	3,945	–	–	﹤0.01%	5162
2023 Q3	$5.13K	Hold	3,945	–	–	﹤0.01%	5243
2023 Q2	$6.39K	Sell	3,945 -1,075	-21%	-$2.1K	﹤0.01%	5291
2023 Q1	$10.7K	Sell	5,020 -11,261	-69%	-$34.4K	﹤0.01%	5317
2022 Q4	$60.2K	Sell	16,281 -483,398	-97%	-$633K	﹤0.01%	5182
2022 Q3	$373K	Sell	499,679 -13,992	-3%	-$11.2K	﹤0.01%	4809
2022 Q2	$400K	Sell	513,671 -13,725	-3%	-$10.2K	﹤0.01%	4845
2022 Q1	$477K	Buy	527,396 +39,482	+8%	+$132K	﹤0.01%	4880
2021 Q4	$3.91M	Buy	487,914 +433,485	+796%	+$3.3M	﹤0.01%	4102
2021 Q3	$455K	Buy	54,429 +24,396	+81%	+$159K	﹤0.01%	4779
2021 Q2	$202K	Buy	30,033 +28,135	+1,482%	+$181K	﹤0.01%	4892
2021 Q1	$12K	Sell	1,898 -23,075	-92%	-$118K	﹤0.01%	5073
2020 Q4	$105K	Sell	24,973 -458,233	-95%	-$1.93M	﹤0.01%	4574
2020 Q3	$2.31M	Sell	483,206 -43,903	-8%	-$230K	﹤0.01%	3863
2020 Q2	$3.21M	Buy	527,109 +90,039	+21%	+$486K	﹤0.01%	3688
2020 Q1	$2.4M	Sell	437,070 -28,492	-6%	-$219K	﹤0.01%	3600
2019 Q4	$4.61M	Sell	465,562 -332,566	-42%	-$2.59M	﹤0.01%	3530
2019 Q3	$4.6M	Sell	798,128 -6,350	-0.8%	-$50.7K	﹤0.01%	3505
2019 Q2	$7.32M	Buy	804,478 +17,234	+2%	+$203K	﹤0.01%	3394
2019 Q1	$10.9M	Buy	787,244 +86,149	+12%	+$1.29M	﹤0.01%	3075
2018 Q4	$11.1M	Buy	+701,095	New	+$12.9M	﹤0.01%	3028

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock's PRQR Position: Q2 2026 in Review

BlackRock held its ProQR Therapeutics (PRQR) position steady in Q2 2026 at 3,945 shares worth $7.34K. The position accounts for ﹤0.01% of the portfolio, ranked #5466.

BlackRock first reported a position in PRQR in Q4 2018 and has held it in 31 quarters since. The position peaked at $11.1M in Q4 2018. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

BlackRock held 3,945 shares of ProQR Therapeutics worth $7.34K as of Q2 2026.
BlackRock left its ProQR Therapeutics share count unchanged in Q2 2026.
ProQR Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5466 holding.
BlackRock first reported a position in ProQR Therapeutics in Q4 2018 and has held it in 31 quarters since.
BlackRock's ProQR Therapeutics position peaked at $11.1M in Q4 2018.
70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.